Research & Development
Ibex announces study results for breast pathology platform
Ibex chief medical officer Dr. Judith Sandbank reported at the congress 100% sensitivity and specificity for pathologists diagnosing breast cancer using the platform.
September 8, 2022
Ibex to expand AI use in Medipath laboratories
Pathologists at Medipath will use the Ibex Galen platform for decision support during primary diagnosis of breast, prostate, and gastric biopsies, Ibex said.
September 1, 2022
Medial EarlySign, Roche partner on lung cancer detection
The goal is to deliver validated clinical machine learning models for lung cancer detection with EarlySign's LungFlag technology. The technology uses a variety of signals, including basic demographic, medical, drug, and routine clinical lab data.
July 7, 2022
Ibex Medical Analytics gets CE Mark for AI-based gastric test
The test was developed by a team of pathologists, data scientists, and software engineers who implemented deep learning technologies and trained algorithms on more than one million image samples, which had been scanned from biopsy slides digitized using digital pathology.
June 14, 2022
AI spots patients at elevated risk for pancreatic cancer
A team of researchers from the U.S. and Denmark used electronic health record (EHR) data from the Danish National Patient Registry to train their algorithm and then tested it on electronic medical records from Mass General Brigham Health Care System in Boston. Their model proved to be highly accurate for predicting patients at high risk for pancreatic cancer on large datasets from both countries.
April 8, 2022
Genialis partners with OncXerna to improve targeted therapy
Genialis' ResponderID will use OncXerna's XernaTME (tumor microenvironment) panel to incorporate the pancancer tumor microenvironment classifier to investigate potentially hundreds of new use cases for personalized therapeutic selection.
April 5, 2022
Quest launches long-COVID testing panels for consumers
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
LumiraDx Q4 revenues drop 65% on lower COVID-19 testing
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Cancer diagnoses still lower a year into COVID-19 pandemic
For a four-month period ending March 2021, the rate of cancer diagnosis was 19% lower than before the pandemic for eight common cancers, according to the study, which was completed by researchers from clinical lab operator Quest Diagnostics. While this represented an improvement over the first four months of the pandemic, the cancer diagnosis rate was still much lower than what might otherwise be expected.
August 31, 2021
RNA testing clarifies the unknown in Ambry cancer study
Earlier this month, the company announced the launch of its +RNAinsight paired testing for RNA and DNA for genes associated with hereditary cancers. The idea is that testing for both provides more information for determining cancer risk.
October 24, 2019
Grail builds case for multicancer blood test
The dataset included 2,414 samples (1,530 with cancer and 884 without cancer) in a substudy of its Circulating Cell-free Genome Atlas (CCGA) study, as well as data for 1,169 participants without cancer in its Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection (STRIVE) study of screening mammography.
September 30, 2019
Blood work tracks immunotherapy in GI cancers
Hyperprogressive disease -- or rapid tumor expansion -- is an effect of immune checkpoint blockade drug therapy that has been getting more attention in recent years with the rising use of PD-1 inhibitors across tumor types. It is distinct from pseudoprogression, where there is tumor growth initially with immunotherapy treatment, but it is followed by a response.
July 25, 2019
Grail mulls LDT option for multicancer liquid biopsy test
The overall detection rate of Grail's LDT for 12 prespecified cancer types tested in the Circulating Cell-free Genome Atlas (CCGA) study was 76%, with 99% specificity; the test's ability to accurately determine the tissue of origin for these tumors ranged from 84% to 92%, the company reported in a statement on May 31 and in a poster presentation at the meeting.
June 2, 2019
Page 1 of 1